Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06466395 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
A Phase 1 study of Refractory Acute Leukemia and Undifferentiated Leukemia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT06466395 is a Phase 1 study of Refractory Acute Leukemia and Undifferentiated Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants, below the 36-participant average among 3 other Refractory Acute Leukemia trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06466395, a Phase 1 study of Refractory Acute Leukemia and Undifferentiated Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Hyper-CVAD
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06466395
The ClinicalTrials.gov registry entry for NCT06466395 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 3 other Refractory Acute Leukemia trials with a reported enrollment target (39% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Acute Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT06466395 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06466395 about?
NCT06466395 is a clinical study titled "A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias". To find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.
What is the current status of trial NCT06466395?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2025-02-18. Estimated completion is 2031-12-31.
What conditions does trial NCT06466395 study?
This clinical trial studies the following conditions: Refractory Acute Leukemia, Undifferentiated Leukemia, Relapsed Acute Leukemia, Bi-Phenotypic Leukemia.
What interventions are being tested in trial NCT06466395?
The interventions under investigation include: Venetoclax (DRUG), Hyper-CVAD (DRUG).
Who is sponsoring clinical trial NCT06466395?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06466395 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Acute Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
RECRUITING · Phase 1
-
A Study of Revumenib and Mezigdomide in People With Leukemia
RECRUITING · Phase 1
-
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.